Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

Risultato della ricerca: Meeting Abstractpeer review

Abstract

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.
Lingua originaleEnglish
pagine (da-a)125-125
Numero di pagine1
RivistaPEDIATRIC RHEUMATOLOGY ONLINE JOURNAL
Volume15
Stato di pubblicazionePublished - 2017

Fingerprint

Entra nei temi di ricerca di 'Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept'. Insieme formano una fingerprint unica.

Cita questo